Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee



ST. GALLEN, Switzerland – (COMMERCIAL THREAD) – Regulatory news:


The Vifor Pharma Group announces today the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Executive Committee of Vifor Pharma as of January 17, 2022.

Hervé Gisserot, of French nationality, is an experienced industrial executive and has a proven track record in the creation and management of organizations in the United States, Europe and Asia-Pacific with extensive experience in launching and accessing the market. . He is from GlaxoSmithKline where he has held several senior vice president positions over the past 13 years. He graduated from the Institut d’Etudes Politiques de Paris (IEP) and followed the General Management program of INSEAD.

With this new appointment, the US President, the Regional Sales Managers, the Rare Diseases BU, the central sales, marketing and pricing teams will report to the Chief Commercial Officer. It’s about leading the organization ahead of the expected approvals and subsequent launches of four pipeline products over the next 18 months, and maximizing the opportunities in our iron portfolio.

Abbas Hussain, CEO of the Vifor Pharma Group, said: “I am delighted that Hervé is joining Vifor Pharma. He brings a wealth of business experience to leading international pharmaceutical companies, driving profitable growth across multiple therapeutic areas and markets. His professional background makes him the ideal candidate to lead the business organization and focus on execution as we accelerate growth to become a multi-brand organization focused on licensing, partnering and product commercialization. in the whole world.


A photo of Hervé Gisserot is available for download at

About the Vifor Pharma Group

The Vifor Pharma Group is a global pharmaceutical company. It aims to become the world leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-centric solutions. The Vifor Pharma Group strives to help patients around the world with severe and chronic illnesses lead better and healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group occupies a leading position in all of its main activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). The Vifor Pharma group is headquartered in Switzerland and is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

For more information, please visit



Comments are closed.